Elevai Biosciences, a subsidiary of Elevai Labs (ELAB), released past preclinical data from 2022 for EL-32, a pioneering dual-action blocker targeting myostatin and activin-A. Preclinical results generated from our licensing partner in a 2022 study indicated that EL-32 may offer a breakthrough approach to obesity treatment by simultaneously preserving muscle mass and reducing fat mass when used alongside popular weight loss therapies such as GLP-1 receptor agonists. Highlights from the results of these studies include: Enhanced grip strength, with notable, statistically significant increases observed at week 15. Improved motor performance, evidenced by longer, statistically significant rotarod latency durations. Optimized body composition, demonstrated by DEXA scans.
Don't Miss out on Research Tools:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ELAB:
- Elevai Labs files two patent applications for EL-22 in muscle loss
- Elevai Labs begins clinical study of topical exosome product
- Biotech Alert: Searches spiking for these stocks today
- Elevai Labs to sell 28.6M shares at 28c in public offering
- Elevai Labs subsidiary announces results from E-series exosome technology